Gland Pharma Limited (NSE:GLAND)

Market Cap	251.51B
Revenue (ttm)	57.29B
Net Income (ttm)	7.04B
Shares Out	164.75M
EPS (ttm)	42.76
PE Ratio	35.70
Forward PE	26.41
Dividend	20.00 (1.31%)
Ex-Dividend Date	n/a

Volume	103,857
Average Volume	167,496
Open	1,519.95
Previous Close	1,519.95
Day's Range	1,515.05 - 1,567.70
52-Week Range	1,411.10 - 2,220.95
Beta	0.29
RSI	47.48
Earnings Date	Feb 3, 2025

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 4,217
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLAND

Financial Performance

In 2023, Gland Pharma's revenue was 56.65 billion, an increase of 56.29% compared to the previous year's 36.25 billion. Earnings were 7.72 billion, a decrease of -1.10%.